## 3 Results
In the non-biopsy group, lower liver stiffness values measured by FIB4, ARFI, and TE were noted in the CHB subgroup in comparison to the CHC subgroup [(B \(\
eq\) C); Table 2a]. CAP levels were higher in the NBNC subgroup than in the CHC subgroup (N \(\
eq\) C). \begin{table}
\begin{tabular}{l l l l l}  & \multicolumn{3}{c}{**(a)**} \\ \hline  & **NAFLD (N)** & **CHB (B)** & **CHC (C)** & \\  & **N = 66** & **N = 82** & **N = 87** & **Multiple Comparisons** \\ \hline Mean ARFI, m/sec & \(1.40\pm 0.59\) & \(1.24\pm 0.36\) & \(1.57\pm 0.60\) & B \(\
eq\) C \\ Location A & \(1.40\pm 0.61\) & \(1.24\pm 0.37\) & \(1.57\pm 0.60\) & B \(\
eq\) (N = C) \\ Location B & \(1.38\pm 0.61\) & \(1.24\pm 0.36\) & \(1.57\pm 0.61\) & B \(\
eq\) (N = C) \\ IQR/Median & \(0.08\pm 0.03\) & \(0.08\pm 0.03\) & \(0.08\pm 0.03\) & NS \\ TE, kPa & \(10.00\pm 10.14\) & \(8.43\pm 8.82\) & \(11.84\pm 9.85\) & B \(\
eq\) C \\ IQR/Med & \(0.11\pm 0.11\) & \(0.10\pm 0.05\) & \(0.09\pm 0.04\) & NS \\ CAP, dB/m & \(265.3\pm 54.2\) & \(256.7\pm 54.5\) & \(249.2\pm 52.4\) & NS \\ FIB4 & \(2.47\pm 2.46\) & \(2.27\pm 1.89\) & \(3.43\pm 2.44\) & (N = B) \(\
eq\) C \\ \hline \end{tabular}
\end{table} 
Table 2: (a) Liver fibrosis and steatosis parameters in patients who did not receive liver histology study; (b) Liver fibrosis and steatosis parameters in patients who received liver histology study. \begin{table}
\begin{tabular}{l l l l l}  & \multicolumn{3}{c}{**(b)**} \\ \hline
**Total Cases** & **NAFLD (N) 125** & **HBV (B) 70** & **HCV (C) 26** & **Multiple Comparisons** \\ \hline Male & \(75\) (\(60.0\) \(\%\)) & \(40\) (\(57.1\) \(\%\)) & \(11\) (\(42.3\) \(\%\)) & NS \\ HCC & \(1\) (\(0.8\) \(\%\)) & \(9\) (\(12.9\) \(\%\)) & \(4\) (\(15.4\) \(\%\)) & N \(\
eq\) (B = C) \\ Age (year) & \(49.85\pm 13.43\) & \(52.03\pm 11.01\) & \(57.91\pm 8.35\) & N \(\
eq\) C \\ Body mass index & \(27.95\pm 3.97\) & \(26.60\pm 4.83\) & \(27.34\pm 4.42\) & NS \\ AST (IU/L) & \(58.22\pm 29.21\) & \(55.27\pm 40.33\) & \(68.92\pm 40.30\) & NS \\ ALT (IUL) & \(92.70\pm 41.16\) & \(73.07\pm 50.14\) & \(76.23\pm 55.55\) & N \(\
eq\) B \\ Bilirubin (mg/dL) & \(0.74\pm 0.34\) & \(0.91\pm 0.87\) & \(0.81\pm 0.26\) & NS \\ Platelets (\(10^{9}\)/L) & \(251.0\pm 64.1\) & \(191.2\pm 60.8\) & \(189.1\pm 73.8\) & N \(\
eq\) (B = C) \\ Prothrombin time INR & \(1.03\pm 0.11\) & \(1.08\pm 0.08\) & \(1.13\pm 0.11\) & N \(\
eq\) (B = C) \\
3 & \(30\) (\(24.0\) \(\%\)) & \(19\) (\(27.1\) \(\%\)) & \(9\) (\(34.6\)\(\%\)) & \\
2 & \(9\) (\(7.2\) \(\%\)) & \(18\) (\(25.7\)\(\%\)) & \(2\) (\(7.7\)\(\%\)) & \\ \(\leq\)1 & \(79\) (\(63.2\) \(\%\)) & \(20\) (\(28.6\)\(\%\)) & \(6\) (\(23.1\)\(\%\)) & \\ Steatosis grade & \(0\) (\(<\)\(5\%\) & \(0\) (\(0\) \(\%\)) & \(27\) (\(38.6\)\(\%\)) & \(9\) (\(34.6\)\(\%\)) & N \(\
eq\) (B = C) \\
1 5–\(33\)\% & \(29\) (\(23.2\) \(\%\)) & \(26\) (\(37.1\)\(\%\)) & \(9\) (\(34.6\)\(\%\)) & \\
2 34–\(66\)\% & \(35\) (\(28.0\) \(\%\)) & \(6\) (\(8.6\)\(\%\)) & \(4\) (\(15.4\)\(\%\)) & \\
3 \(>\)\(66\)\% & \(61\) (\(48.8\) \(\%\)) & \(11\) (\(15.7\)\(\%\)) & \(4\) (\(15.4\)\(\%\)) & \\ \hline \end{tabular}
\end{table} 
Table 1: _Cont._In the biopsy group, liver fibrosis scores more severe in the viral hepatitis subgroups than the NBNC subgroup [N \(\
eq\) (B = C); Table 2b]. The liver stiffness measurements were generally more severe in CHC than in NAFLD [(N \(\
eq\) C); Table 2a]. The fat cell fraction was higher in the NAFLD subgroup [N \(\
eq\) (B = C)] than in the viral hepatitis groups. The CAP values were correlated with the histology fat cell fractions (R\({}^{2}\) linear = 0.615, Spearman's rho \(p\) < 0.001) in all participants. However, the correlation reached a plateau when the CAP values were \(\geq\)290 dB/m (R\({}^{2}\) linear = 0.009). The correlation between the TE and the mean ARFI value in total cases was good (R\({}^{2}\) = 0.798, [PERSON]'s rho \(p\) < 0.001).